Related Experiment Video
Updated: Sep 20, 2025

07:30
Evaluation of the Cognitive Performance of Hypertensive Patients with Silent Cerebrovascular Lesions
Published on: April 23, 2021
3.1K
Vascular Cognitive Impairment and Dementia.
Summary
Vascular cognitive impairment and dementia (VCID) management focuses on controlling cardiovascular risk factors and optimizing treatment for cerebrovascular diseases. Early diagnosis through clinical evaluation and neuroimaging is crucial for effective intervention and prevention.
Area of Science:
- Neurology
- Geriatrics
- Public Health
Background:
- Vascular cognitive impairment and dementia (VCID) is a significant cause of cognitive decline, distinct from degenerative dementias.
- Understanding the diverse pathophysiology of VCID, including various cerebrovascular diseases, is essential for effective management.
- VCID represents the leading nondegenerative cause of dementia, highlighting the importance of preventative strategies.
Purpose of the Study:
- To provide a comprehensive overview of vascular cognitive impairment and dementia (VCID).
- To discuss epidemiology, pathophysiology, clinical approaches, and management strategies for VCID.
- To emphasize the role of understanding cerebrovascular diseases and managing risk factors in VCID.
Main Methods:
- Review of current literature on vascular cognitive impairment and dementia.
- Analysis of diagnostic criteria and phenotypic categories for vascular dementia.
- Examination of risk factor management and therapeutic interventions for VCID.
Main Results:
- VCID pathophysiology is heterogeneous, with diagnostic criteria categorizing it into four main phenotypes.
- Control of cardiovascular risk factors (blood pressure, cholesterol, blood sugar) is key for VCID prevention.
- Cerebral amyloid angiopathy requires specific risk factor management due to hemorrhage risk.
- Cognitive rehabilitation shows promise in improving global cognitive function in VCID patients.
Conclusions:
- Diagnosis relies on thorough clinical evaluation and neuroimaging.
- Optimizing management of identified risk factors is paramount for preventing and managing VCID.
- Symptomatic management and secondary prevention are crucial after vascular brain injury.
Related Concept Videos
Dementia
182
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
182
Cognitive Development During Adulthood
317
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
317
Alzheimer's Disease: Overview
689
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
689
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Ischemic Heart Disease: Overview
1.4K
Ischemic heart disease occurs when the heart's blood supply dwindles, causing an ominous lack of oxygen and nutrients. This deficiency, stemming from reduced or obstructed blood flow, spells danger, leading to heart muscle damage and dysfunction.
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
Atherosclerosis, the primary malefactor, orchestrates this dangerous condition. It manifests as the accumulation of fatty deposits, akin to insidious plaques, within arterial walls. As time elapses, these plaques metamorphose, hardening and...
1.4K
Alzheimer's Disease: Treatment
266
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
266

